Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The company is starting four new pivotal trials this year.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
Tecvayli and Hernexeos might get speedy approval decisions.
RMC-5127 becomes the company’s fourth clinical project.
